Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035384 · ClinicalTrials.gov registry record
Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 69
- Enrollment target
NCT02035384 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 69 participants.
The verdict
NCT02035384 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 69 participants
- Enrollment target
Study Summary
This study is conducted in Europe, and North and South America. The aim of this study is to provide additional documentation of the immunogenicity, and obtain additional clinical data, of turoctocog alfa in the setting of normal clinical practise in patients previously treated with a factor VIII agent (FVIII).
Interventions
- DRUG turoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2014-06-05 |
| Est. Completion | 2020-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035384
The ClinicalTrials.gov registry entry for NCT02035384 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which turoctocog alfa is the first listed.
NCT02035384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02035384 about?
NCT02035384 is a clinical study titled "Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A". This study is conducted in Europe, and North and South America. The aim of this study is to provide additional documentation of the immunogenicity, and obtain additional clinical data, of turoctocog alfa in the setting of normal clinical practise in patients previously treated with a factor VIII age...
What is the current status of trial NCT02035384?
This trial is currently completed. The enrollment target is 69 participants. The study started on 2014-06-05. Estimated completion is 2020-01-15.
What interventions are being tested in trial NCT02035384?
The interventions under investigation include: turoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT02035384?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.